Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) Interest Expenses: 2009-2025

Historic Interest Expenses for UNITED THERAPEUTICS (UTHR) over the last 17 years, with Sep 2025 value amounting to $3.0 million.

  • UNITED THERAPEUTICS's Interest Expenses fell 70.30% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.3 million, marking a year-over-year decrease of 51.50%. This contributed to the annual value of $42.9 million for FY2024, which is 27.66% down from last year.
  • Per UNITED THERAPEUTICS's latest filing, its Interest Expenses stood at $3.0 million for Q3 2025, which was down 58.90% from $7.3 million recorded in Q2 2025.
  • In the past 5 years, UNITED THERAPEUTICS's Interest Expenses ranged from a high of $15.6 million in Q3 2023 and a low of $3.0 million during Q3 2025.
  • In the last 3 years, UNITED THERAPEUTICS's Interest Expenses had a median value of $11.6 million in 2024 and averaged $10.8 million.
  • Its Interest Expenses has fluctuated over the past 5 years, first spiked by 193.62% in 2023, then tumbled by 70.30% in 2025.
  • UNITED THERAPEUTICS's Interest Expenses (Quarterly) stood at $4.7 million in 2021, then soared by 161.70% to $12.3 million in 2022, then grew by 22.76% to $15.1 million in 2023, then crashed by 47.68% to $7.9 million in 2024, then plummeted by 70.30% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, $7.3 million for Q2 2025, and $6.1 million during Q1 2025.